INTRODUCTION
Dyslipidemia is common in patients with diabetes and prediabetes and is a risk factor for cardiovascular disease (CVD) [1] . Medical guidelines from the American Diabetes [1, 2] .
Despite the beneficial effects of statins on low-density lipoprotein cholesterol (LDL-C), some patients may have a residual risk of cardiovascular (CV) events, CV death, and myocardial infarction due to the effects of elevated triglycerides (TGs) [3, 4] , as statins achieve only a 10-30% reduction in TGs [5] . The Residual Risk Reduction Initiative defines residual CV risk as the risk of CV events that persists despite achievement of LDL-C, blood pressure, and glycemic treatment goals [6] .
Thus, add-on therapy may be needed to control TGs and TG-rich lipoproteins and to further reduce risk in some statin-treated patients. Such adjunct therapies include omega-3 fatty acids (OM3FAs) [2] .
The OM3FAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have numerous known CV benefits in patients with dyslipidemia such as antidysrhythmic, antiatherogenic, antiinflammatory, antithrombotic, and antihypertensive effects, and in particular, reduction of TGs [7, 8] . OM3FA therapies are approved by the United States Food and Drug
Administration for use as adjunct to diet to reduce TGs in adult patients with severe (C500 mg/dL) hypertriglyceridemia. Approved formulations commercially available at the time of this analysis were omega-3-acid ethyl esters (OM3EE; Lovaza Ò ; GlaxoSmithKline, Research Triangle Park, North Carolina, USA), a formulation that contains a combination of the ethyl esters of EPA and DHA [9] , and icosapent ethyl (IPE; Vascepa Ò ; Amarin Pharma Inc., Bedminster, New Jersey, USA), a high-purity prescription form of EPA ethyl ester [10] . Each is administered as a daily dose of 4 g. Notably, OM3FA formulations that contain DHA have been associated with increases in LDL-C, but EPA does not increase LDL-C [11] . Similarly, the prescribing information of OM3EE warns that increases in LDL-C have occurred in some patients and recommends periodic LDL-C monitoring [9] , while the prescribing information of IPE does not contain this warning.
Based on the known beneficial effects of OM3FAs, and in an effort to reduce TG and/or CV risk in patients in our private endocrinology practice, we began prescribing OM3EE to patients based on our overall assessments of their clinical status and potential for CV risk. In addition to the known possible increase in LDL-C associated with OM3EE use and consistent with the Adverse Reactions section of the OM3EE prescribing information [9] , we noted that gastrointestinal problems and fishy eructation [12] were among the side effects that interfered with compliance in our practice. When IPE became commercially available in 2013, we noted that it contained purified EPA, which could reduce TG without the increases in LDL-C associated with OM3EE, and that the incidence of eructation and gastrointestinal upset in statin-treated patients was lower than that seen in statin-treated patients receiving placebo [10, 13, 14] . In our clinical judgment, IPE had the potential for fewer side effects and to be better tolerated, with no adverse effects on LDL-C, so we began switching our patients from OM3EE to IPE. The objective of the current analysis was to retrospectively assess the lipid profiles of adult patients with diabetes or prediabetes who had been receiving OM3EE and were subsequently switched to IPE.
METHODS

Study Design
This was a retrospective chart review of patients in a private endocrinology practice in Houston, Texas. Records for diabetic and prediabetic patients who had been receiving OM3EE and subsequently underwent a switch to IPE were identified through a search of Electronic Clinical Works (ECW)/Electronic Health Records (EHR). The authors received approval from the Western Institutional Review Board, Puyallup, WA, for the conduct of this study.
This article does not contain any new studies with human or animal subjects performed by any of the authors.
Patients and Treatment
Patients were eligible if they had well-controlled diabetes or prediabetes and hyperlipidemia; had been switched from OM3EE 4 g/day to IPE 4 g/ day; had been taking IPE for more than 
RESULTS
Patients
Of the patient records retrieved from the ECW/ EHR database, ten met the inclusion criteria and were analyzed. The population included eight adult males and two adult females ranging in age from 42 to 66 years (Table 1) (Table 1 ). Eight patients also had hypertension (Table 1) .
Following the switch from OM3EE to IPE, no gastrointestinal adverse events or fishy odor/ eructation were reported. IPE was well tolerated.
Effects on Lipid Parameters
Percentage changes in lipid values after the switch from OM3EE to IPE are shown in Table 1 . Lipid levels for patients while on OM3EE before the switch to IPE ranged from 53 to 168 mg/dL for LDL-C, 65 to 278 mg/dL for TG, 66 to 210 mg/dL for non-HDL-C, 108 to 255 mg/dL for TC, and 37 to 68 mg/dL for HDL-C. Lipid levels for patients while on IPE ranged from 55 to 122 mg/dL for LDL-C, 71 to 213 mg/dL for TG, 71 to 159 mg/dL for non-HDL-C, 110 to 228 mg/dL for TC, and 37 to 86 mg/dL for HDL-C. Figure 1 summarizes the individual lipid levels before and after the switch from OM3EE
to IPE. Reductions in LDL-C, TC, and non-HDL-C were observed in eight patients, reductions or no changes in TG were observed in eight patients, and increases or no changes in HDL-C were observed in eight patients.
DISCUSSION
In this retrospective analysis of patients with diabetes or prediabetes, we sought to evaluate the lipid profiles in patients switched from OM3EE to IPE in our private clinical endocrinology practice. We found that, in most cases, patients experienced decreases in LDL-C, TG, non-HDL-C, and TC and increases in HDL-C following the switch to IPE. Two patients (numbers 4 and 6) experienced increases in LDL-C, TG, non-HDL-C, and TC after switching to IPE, although lipid levels in patient 4 were still within the acceptable range as specified by the AACE [2] and the recent National Lipid Association (NLA) recommendations for patient-centered management of dyslipidemia [16] . In patient 6, the increase in LDL-C was relatively small (from 113 to 116 mg/dL), and TGs were still within the acceptable range as specified by the AACE and NLA. Overall, the effects seen represented improvements in the assessed lipid parameters in most patients.
Our findings are similar to those of other recent reports of patients switched from EPA ? DHA formulations to IPE. Case studies of two patients with type 2 diabetes and dyslipidemia who were switched from either a dietary supplement containing EPA ? DHA or OM3EE to IPE showed improvements in LDL-C, TG, non-HDL-C, and nominal effects on HDL-C [17] . In addition, in a retrospective case series of 14 statin-treated patients with hyperlipidemia from a private practice in 4 Western New York locations, switching from OM3EE to IPE achieved reductions in LDL-C, TGs, non-HDL-C, and TC in most cases [18] . There were three patients in the Western New York study that had diabetes, and all three experienced reductions in non-HDL-C and TC following the switch from OM3EE to IPE. Two of the three patients with diabetes experienced TG reductions; one patient experienced an increase in TG from 62 to 81 mg/dL, which may not be considered clinically significant, as 81 mg/dL is considered to be within the acceptable range as specified by the guidelines of the NLA [16] , AACE [2] , and the Endocrine Society [19] . Two of these three patients also experienced reductions in LDL-C, while one patient had a reported LDL-C increase of 39.8%. However, upon calculating the expected LDL-C level in this patient based upon the Friedewald formula (LDL-C = TC minus HDL-C minus TG/5; all values given in mg/dL) [20] , the LDL-C level in this patient while on OM3EE would be expected to have been 173 mg/dL and not 123 mg/dL as reported, resulting in an actual 0.6% decrease in LDL-C following the switch from OM3EE to IPE. high TGs (C200 and \500 mg/dL) despite statin control of LDL-C (C40 and B115 mg/dL). In a subanalysis of patients with diabetes from the ANCHOR study, IPE 4 g/day significantly decreased median LDL-C by 6.3% (P = 0.02), TGs observed in our analysis. However, the increases in HDL-C in our analysis differ somewhat from the small but significant decreases in HDL-C in the ANCHOR subanalysis. It is unclear why this difference was observed, but may perhaps be attributable to differences in the patient populations, differences in concurrent medications, and/or other unknown factors. Similar to results of clinical trials where tolerability of IPE was comparable to placebo [13, 14] , IPE was well tolerated in our patient population, with no gastrointestinal adverse events reported. Our findings are novel in that we examined the effects of switching from OM3EE to IPE in patients with diabetes or prediabetes, an important patient population with respect to CVD risk. While patients in this analysis may not have been receiving a maximally approved statin dose, each patient was receiving their own maximally tolerated dose. Our experience has been that patients may have difficulty tolerating higher statin doses due to adverse effects such as muscle aches and fatigue.
Diabetes in these patients was well controlled as were TGs in most cases.
It is our opinion that the unmet need of residual CV risk in our patients should be addressed, and thus we prescribe prescription OM3FA products in our endocrinology practice. 
CONCLUSIONS
In this analysis of patients with prediabetes or diabetes in a private endocrinology clinical practice who were switched from OM3EE to IPE, LDL-C, TG, non-HDL-C, TC, and HDL-C improved in most patients. IPE was well tolerated after switching from OM3EE. Taken together, the evidence to date suggests that treatment with IPE produces beneficial effects in patients with diabetes who may also be receiving statin therapy, and that switching patients from OM3EE to IPE offers a therapeutic option that results in a beneficial lipid profile. 
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